174 related articles for article (PubMed ID: 11513186)
21. Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
Shiffman ML; Diago M; Tran A; Pockros P; Reindollar R; Prati D; Rodríguez-Torres M; Lardelli P; Blotner S; Zeuzem S
Clin Gastroenterol Hepatol; 2006 May; 4(5):645-52. PubMed ID: 16630770
[TBL] [Abstract][Full Text] [Related]
22. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
23. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
[TBL] [Abstract][Full Text] [Related]
24. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.
Fargion S; Fracanzani AL; Rossini A; Borzio M; Riggio O; Belloni G; Bissoli F; Ceriani R; Ballarè M; Massari M; Trischitta C; Fiore P; Orlandi A; Morini L; Mattioli M; Oldani S; Cesana B; Fiorelli G
Am J Gastroenterol; 2002 May; 97(5):1204-10. PubMed ID: 12014729
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha.
Truong BX; Seo Y; Kato M; Hamano K; Ninomiya T; Katayama M; Kato H; Yano Y; Hayashi Y; Kasuga M
Int J Mol Med; 2005 Aug; 16(2):279-84. PubMed ID: 16012762
[TBL] [Abstract][Full Text] [Related]
26. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
Yu ML; Dai CY; Lee LP; Hou NJ; Hsieh MY; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Liver Int; 2006 Dec; 26(10):1187-95. PubMed ID: 17105583
[TBL] [Abstract][Full Text] [Related]
27. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
28. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
29. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection?
Sanai FM; Benmousa A; Al-Hussaini H; Ashraf S; Alhafi O; Abdo AA; Alameri HF; Akbar HO; Bzeizi KI
Liver Int; 2008 Aug; 28(7):1011-8. PubMed ID: 18384520
[TBL] [Abstract][Full Text] [Related]
30. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.
Piton A; Poynard T; Imbert-Bismut F; Khalil L; Delattre J; Pelissier E; Sansonetti N; Opolon P
Hepatology; 1998 May; 27(5):1213-9. PubMed ID: 9581673
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of the analogue of natural Schisandrin C (HpPro) in treatment of liver diseases: an experience in Indonesian patients.
Akbar N; Tahir RA; Santoso WD; Soemarno ; Sumaryono ; Noer HM; Liu G
Chin Med J (Engl); 1998 Mar; 111(3):248-51. PubMed ID: 10374427
[TBL] [Abstract][Full Text] [Related]
33. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks.
Manns MP; Wedemeyer H; Singer A; Khomutjanskaja N; Dienes HP; Roskams T; Goldin R; Hehnke U; Inoue H;
J Viral Hepat; 2012 Aug; 19(8):537-46. PubMed ID: 22762137
[TBL] [Abstract][Full Text] [Related]
34. [Isoprinosine therapy in chronic hepatitis C (multicenter placebo-controlled double-blind prospective study)].
Pár A; Beró T; Brasch G; Gógl A; Kamarás G; Méhesfalvi E; Ozsvár Z; Paál M; Szipöcs I; Telegdy L
Orv Hetil; 1993 May; 134(19):1015-9. PubMed ID: 7684118
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C.
Hwang SJ; Lee SD; Chan CY; Lu RH; Chang FY
Am J Gastroenterol; 1999 Sep; 94(9):2496-500. PubMed ID: 10484014
[TBL] [Abstract][Full Text] [Related]
36. 'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients.
van Rossum TG; de Jong FH; Hop WC; Boomsma F; Schalm SW
J Gastroenterol Hepatol; 2001 Jul; 16(7):789-95. PubMed ID: 11446888
[TBL] [Abstract][Full Text] [Related]
37. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
Fried MW; Navarro VJ; Afdhal N; Belle SH; Wahed AS; Hawke RL; Doo E; Meyers CM; Reddy KR;
JAMA; 2012 Jul; 308(3):274-82. PubMed ID: 22797645
[TBL] [Abstract][Full Text] [Related]
38. Nutritional therapy of chronic hepatitis by whey protein (non-heated).
Watanabe A; Okada K; Shimizu Y; Wakabayashi H; Higuchi K; Niiya K; Kuwabara Y; Yasuyama T; Ito H; Tsukishiro T; Kondoh Y; Emi N; Kohri H
J Med; 2000; 31(5-6):283-302. PubMed ID: 11508322
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of chronic hepatitis C by bicyclum, a randomized double-blind placebo controlled trial].
Yao G; Ji Y; Zhou X; Wang Q; Wu W
Zhonghua Yi Xue Za Zhi; 2002 Jul; 82(14):958-60. PubMed ID: 12181088
[TBL] [Abstract][Full Text] [Related]
40. Report of a case showing a recovery from liver cirrhosis to chronic hepatitis, type C, after glycyrrhizin injection for 2 years and a sustained response by the following interferon therapy.
Watanabe M; Uchida Y; Sato S; Moritani M; Hamamoto S; Mishiro T; Akagi S; Kinoshita Y; Kohge N
Am J Gastroenterol; 2001 Jun; 96(6):1947-9. PubMed ID: 11419866
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
